Humans Neoplasm Grading Neoplasm Invasiveness Neoplasm Recurrence Local/*pathology Neoplasm Staging Neoplasm Residual *Reoperation Risk Factors Survival Rate Urinary Bladder/pathology Urinary Bladder Neoplasms/*pathology/*surgery Bladder Cancer Detrusor Muscle Progression Re-resection Recurrence Upstaging

Age Factors Biomarkers Tumor DNA Methylation/genetics Humans Neoplasm Staging Promoter Regions Genetic Proportional Hazards Models Sex Factors Survival Analysis Tumor Suppressor Proteins/*genetics Urinary Bladder Neoplasms/*genetics/*pathology

Humans Neoplasm Recurrence Local/*diagnosis Obesity/complications/*diagnosis Risk Factors Urinary Bladder Neoplasms/*diagnosis Bladder cancer Obesity Recurrence Survival

Antineoplastic Agents/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Chemotherapy Adjuvant Cystectomy Cystoscopy Humans Lymph Node Excision Muscle Smooth/*pathology *Neoadjuvant Therapy Neoplasm Invasiveness *Organ Sparing Treatments Progression-Free Survival Proportional Hazards Models *Radiotherapy Adjuvant Survival Rate Urinary Bladder Neoplasms/pathology/*therapy Bladder preserving Cancer Muscle invasive Radical cystectomy Trimodal

Aged Diabetes Mellitus Type 2/complications/*drug therapy Disease Progression Disease-Free Survival Female Humans Hypoglycemic Agents/*therapeutic use Male Metformin/*therapeutic use Middle Aged Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Urinary Bladder Neoplasms/etiology/*mortality

Chemoradiotherapy/*methods Combined Modality Therapy Cystectomy/*adverse effects/methods Disease-Free Survival Female Humans Male Middle Aged Neoplasm Metastasis Robotic Surgical Procedures/*adverse effects/methods Treatment Outcome Urinary Bladder Neoplasms/diagnostic imaging/*therapy Bladder cancer Cystectomy Multi-modality treatment Port-site metastasis Rare complications

Aged Aged 80 and over Chemoradiotherapy/*mortality/*statistics & numerical data Combined Modality Therapy Cystectomy/*mortality/*statistics & numerical data Disease-Free Survival Female Humans Male Middle Aged Neoplasm Invasiveness Postoperative Complications/mortality/prevention & control Prevalence Radiation Injuries/mortality/prevention & control Risk Factors Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/*therapy

*Biomarkers Tumor Disease Progression Gene Expression Humans Matrix Metalloproteinases/*genetics/metabolism Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*genetics/metabolism/*mortality/pathology bladder cancer matrix metalloproteinases meta-analysis

Anemia/*complications Cystectomy/*methods Female Humans Male Preoperative Period Proportional Hazards Models Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*surgery Anemia Bladder cancer Hemoglobin Mortality Recurrence

Cation Transport Proteins/*genetics Glutathione Peroxidase/*genetics Humans Neoplasm Recurrence Local/genetics Polymorphism Genetic Survival Analysis Urinary Bladder Neoplasms/genetics/*pathology Glutathione Peroxidase GPX1 Nmibc Nramp1 d534n hGPX1 Pro168Leu meta-analysis recurrence

Age Factors Aged Aged 80 and over Clinical Decision-Making *Cystectomy/adverse effects/mortality Disease-Free Survival Female Geriatric Assessment Humans Life Expectancy Male Middle Aged Neoplasm Invasiveness Odds Ratio Patient Selection Quality of Life Radiotherapy/adverse effects/mortality Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Complications Elderly Mibc Outcome

Cystectomy/*methods Disease-Free Survival Humans Lymphatic Metastasis *Margins of Excision Neoplasm Recurrence Local Neoplasm Staging Prognosis Treatment Outcome Urinary Bladder Neoplasms/pathology/*surgery bladder cancer meta-analysis outcome radical cystectomy surgical margin status

Aged Aged 80 and over *Biomarkers Tumor Cluster Analysis Cohort Studies Female Gene Expression Profiling Humans Immunohistochemistry Male Middle Aged Mutation Neoplasm Invasiveness Neoplasm Staging Neoplasms Basal Cell/*diagnosis/genetics/*metabolism/mortality Prognosis Survival Analysis Tissue Array Analysis Urinary Bladder Neoplasms/*diagnosis/genetics/*metabolism/mortality Biomarker Bladder cancer

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant Cisplatin/administration & dosage Humans Neoadjuvant Therapy Neoplasm Invasiveness Urinary Bladder Neoplasms/*drug therapy/mortality/pathology Bladder cancer Chemotherapy Neoadjuvant Platinum Survival article.

Asian People Biomarkers Tumor Humans Ki-67 Antigen/*immunology Prognosis Proportional Hazards Models Survival Analysis Urinary Bladder Neoplasms/ethnology/*immunology/*mortality White People

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant Cisplatin/administration & dosage *Cystectomy/methods Evidence-Based Medicine Humans *Lymph Node Excision Neoadjuvant Therapy/*methods Neoplasm Invasiveness Organ Sparing Treatments/methods Randomized Controlled Trials as Topic Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/*pathology/*therapy adjuvant chemotherapy bladder cancer bladder-sparing therapy lymph node dissection neoadjuvant chemotherapy radical cystectomy

*Aminolevulinic Acid Cystectomy/methods Disease-Free Survival Humans Neoplasm Recurrence Local *Photosensitizing Agents Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/diagnostic imaging/*surgery 5-aminolevulinic acid non-muscle invasive bladder cancer photodynamic diagnosis recurrence-free survival transurethral resection

Administration Intravesical Antineoplastic Combined Chemotherapy Protocols/*administration & dosage Carcinoma Transitional Cell/mortality/*pathology/*therapy Disease Progression Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Mitomycin/administration & dosage Neoplasm Recurrence Local/*prevention & control Neoplasm Staging Randomized Controlled Trials as Topic Risk Factors Survival Rate Thiotepa/administration & dosage Time Factors Urinary Bladder Neoplasms/mortality/*pathology/*therapy Chemotherapy Meta-analysis Non–muscle-invasive bladder cancer Single instillation Systematic review

Adult Aged Aged 80 and over Biomarkers Tumor/*metabolism Cyclin-Dependent Kinase Inhibitor p16/*metabolism *Down-Regulation Female Gene Expression Regulation Neoplastic Humans Lymphatic Metastasis Male Middle Aged Prognosis Survival Analysis Urinary Bladder Neoplasms/metabolism/mortality/*pathology